Literature DB >> 18581137

Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers.

Annegret Müller1, Dirk Zielinski, Nicolaus Friedrichs, Barbara Oberschmid, Sabine Merkelbach-Bruse, Hans K Schackert, Markus Linnebacher, Magnus von Knebel Doeberitz, Reinhard Büttner, Josef Rüschoff.   

Abstract

Based on the principle of nonsense-mediated mRNA decay, we sought to identify MLH1 or MSH2-deficient colorectal tumours through relative quantification of mRNA expression with real-time PCR (RT-PCR) analysis. MLH1 and MSH2 mRNAs were almost equally expressed as defined by MLH1 to MSH2 transcript ratio (mean 1.41) in microsatellite stable, mismatch repair (MMR) proficient tumours (n = 16). A close correlation between loss of protein expression and MMR-mRNA levels was found in highly microsatellite instable (MSI-H) tumours deficient of MLH1 or MSH2. MLH1/MSH2 ratio was low in 11 sporadic and nine hereditary MLH1-deficient carcinomas (mean 0.51), whereas the ratio was high in 17 MSH2-deficient hereditary non-polyposis colorectal cancer (HNPCC) associated carcinomas (mean 6.8). Notably, in the normal tissues of HNPCC patients with MSH2 mutations, the MLH1/MSH2 transcript ratios were significantly elevated (ratio > 2.0) as compared to the ratios of normal mucosa in patients with MMR-proficient tumours (27 of 32 ratio < 2.0; p = 0.00113). Analysis of B-lymphocytes of HNPCC patients with proven MMR gene mutation confirmed these findings. In conclusion, RT-PCR allows relative quantification of MMR gene mRNA expression in formalin-fixed and paraffin-embedded tissue. Furthermore, this approach enables quantification of haploinsufficiency due to nonsense-mediated mRNA decay in normal tissue and B-lymphocytes from patients carrying MSH2 germline mutations and may be useful for identification of asymptomatic carriers of pathogenic germline mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18581137     DOI: 10.1007/s00428-008-0637-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  A large deletion in the adRP gene PRPF31: evidence that haploinsufficiency is the cause of disease.

Authors:  Leen Abu-Safieh; Eranga N Vithana; Irmela Mantel; Graham E Holder; Lucia Pelosini; Alan C Bird; Shomi S Bhattacharya
Journal:  Mol Vis       Date:  2006-04-18       Impact factor: 2.367

2.  Analysis of the allele-specific expression of the mismatch repair gene MLH1 using a simple DHPLC-Based Method.

Authors:  Isabelle Tournier; Grégory Raux; Fréderic Di Fiore; Isabelle Maréchal; Carole Leclerc; Cosette Martin; Qing Wang; Marie-Pierre Buisine; Dominique Stoppa-Lyonnet; Sylviane Olschwang; Thierry Frébourg; Mario Tosi
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878

3.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer.

Authors:  R Salovaara; A Loukola; P Kristo; H Kääriäinen; H Ahtola; M Eskelinen; N Härkönen; R Julkunen; E Kangas; S Ojala; J Tulikoura; E Valkamo; H Järvinen; J P Mecklin; L A Aaltonen; A de la Chapelle
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

Review 4.  Deficient DNA mismatch repair: a common etiologic factor for colon cancer.

Authors:  P Peltomäki
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

5.  Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.

Authors:  M Linnebacher; J Gebert; W Rudy; S Woerner; Y P Yuan; P Bork; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-07-01       Impact factor: 7.396

6.  Microsatellite instability-a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer.

Authors:  C Lamberti; R Kruse; C Ruelfs; R Caspari; Y Wang; M Jungck; M Mathiak; H R Malayeri; W Friedl; T Sauerbruch; P Propping
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

7.  Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression.

Authors:  W Dietmaier; S Wallinger; T Bocker; F Kullmann; R Fishel; J Rüschoff
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

8.  Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia.

Authors:  Alfa H C Bai; Joanna H M Tong; Ka-Fai To; Michael W Y Chan; Ellen P S Man; Kwok-Wai Lo; Janet F Y Lee; Joseph J Y Sung; Wai K Leung
Journal:  Int J Cancer       Date:  2004-12-10       Impact factor: 7.396

9.  Two novel mutations and evidence for haploinsufficiency of the ADAR gene in dyschromatosis symmetrica hereditaria.

Authors:  Q Liu; L Jiang; W-L Liu; X-J Kang; Y Ao; M Sun; Y Luo; Y Song; W H Y Lo; X Zhang
Journal:  Br J Dermatol       Date:  2006-04       Impact factor: 9.302

10.  The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study.

Authors:  W Müller; L J Burgart; R Krause-Paulus; S N Thibodeau; M Almeida; T B Edmonston; C R Boland; C Sutter; J R Jass; A Lindblom; J Lubinski; K MacDermot; D S Sanders; H Morreau; A Müller; C Oliani; T Orntoft; M Ponz De Leon; C Rosty; M Rodriguez-Bigas; J Rüschoff; A Ruszkiewicz; J Sabourin; R Salovaara; G Möslein
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

View more
  4 in total

1.  Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study.

Authors:  Lars Henrik Jensen; Anders Aamann Rasmussen; Lene Byriel; Hidekazu Kuramochi; Dorthe Gylling Crüger; Jan Lindebjerg; Peter V Danenberg; Anders Jakobsen; Kathleen Danenberg
Journal:  Cell Oncol (Dordr)       Date:  2013-09-12       Impact factor: 6.730

2.  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Authors:  Dimitrios Pectasides; Vasilios Karavasilis; George Papaxoinis; Georgia Gourgioti; Thomas Makatsoris; Georgia Raptou; Eleni Vrettou; Joseph Sgouros; Epaminontas Samantas; George Basdanis; Pavlos Papakostas; Dimitrios Bafaloukos; Vassiliki Kotoula; Haralambos P Kalofonos; Chrisoula D Scopa; George Pentheroudakis; George Fountzilas
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

3.  Pancreatic cancer 'mismatch' in Lynch syndrome.

Authors:  Andrew E Hendifar; Brent K Larson; Rebecca Rojansky; Michelle Guan; Jun Gong; Veronica Placencio; Richard Tuli; Megan Hitchins
Journal:  BMJ Open Gastroenterol       Date:  2019-03-22

4.  Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin.

Authors:  Tetsuya Minegaki; Kohji Takara; Ryohei Hamaguchi; Masayuki Tsujimoto; Kohshi Nishiguchi
Journal:  Oncol Lett       Date:  2012-11-05       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.